Transplant Infectious Disease Secrets Shared! Key Insights on Antibiotic Duration, Oral Antibiotic Conversion, and Fungal Diagnostic Selection

27 February, 2024 12:00 p.m. to 1:00 p.m. EST

  • Advanced Heart Failure & Transplantation
  • Advanced Lung Failure & Transplantation
  • Committees & Communities
  • Infectious Diseases
  • Mechanical Circulatory Support
  • Online Education
  • Past Webinars
  • Pharmacy
  • Professional Communities
  • Webinar
Thumbnail for Infectious Diseases Professional Community Webinars

This webinar will discuss key insights into duration of antibiotic therapy, opportunities for IV to PO antibiotic conversion, and when and how to select fungal diagnostics in thoracic transplant recipients and MCS patients.

Moderators:

Emily Eichenberger, MD, MHS
Amanda Ingemi, PharmD

Presentations

Duration of Antibiotic Therapy for Clinical Syndromes Encountered in Thoracic Transplant and MCS

We will delve into the data behind selecting the appropriate duration of antibiotic therapy for various clinical syndromes commonly encountered in thoracic transplant and mechanical circulatory support patients. This talk will encompass a range of scenarios, including bloodstream infection, pneumonia, and mediastinitis, providing attendees with a comprehensive understanding of tailored antibiotic strategies in these specialized patient groups.

Presented by Nicolas Mueller, MD

Opportunities for IV to PO Conversion in Thoracic Transplant and MCS

We will examine the opportunities and challenges associated with IV to PO (intravenous to oral) antibiotic conversion in thoracic transplant and mechanical circulatory support (MCS) patients. This presentation will highlight key factors in deciding when and how to safely switch from IV to oral antibiotics, discussing how infection type, source, antibiotic class, and bioavailability play a role in this critical decision making.

Presented by Tara Fallah, PharmD

Fungal Diagnostic Stewardship in Thoracic Transplant and MCS

This session will provide an in-depth analysis of the appropriate use of fungal biomarkers, discussing their positive and negative predictive value in a variety of clinical scenarios, outlining specific situations where they are most effective and instances where their use may not be beneficial.

Presented by Nancy Law, DO, MPH

Q&A Session

With all Speakers

Speakers